9 completed, 5 active not recruiting, 3 recruiting, 2 terminated. 11 Phase 2, 4 Phase 3, 3 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow HER2 Positive Breast Carcinoma: new trials by email Literature Review of HER2 Positive Breast Carcinoma trials Research Report on HER2 Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI HER2 Positive Breast Carcinoma | Recruiting | Heinrich-Heine University, Duesseldorf | 460 | 2025-07-18 | 2025-09-24 | |
| Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer HER2 Positive Breast Carcinoma, Neoadjuvant Therapy | Active not recruiting | Chongqing General Hospital | 50 | 2025-01-01 | 2025-03-11 | |
| Validation of TAD in HER-2 with More Than 2 Lymph Nodes Targeted axillary dissection and subsequently a lymphadenectomy - Breast Carcinoma Metastatic in Lymph Node, HER2 Positive Breast Carcinoma | Enrolling by invitation | Fundación para la Investigación del Hospital Clínico de Valencia | 21 | 2024-06-30 | 2025-02-12 | |
| RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study Trastuzumab deruxtecan (DS-8201a) - Radiomic, Radiomics | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 500 | 2024-02-01 | 2025-06-22 | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial Trastuzumab Emtansine, Placebo Administration, Tucatinib - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1056 | 2021-03-02 | 2026-06-15 |
| Nipple Aspirate Fluid in Detecting Breast Cancer Aspiration of Breast, Biospecimen Collection - Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 2 | 2020-12-10 | 2025-02-25 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Abemaciclib, Trastuzumab Emtansine - Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-11-11 | 2022-05-26 | |
| Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer Best Practice, Questionnaire Administration, Rifaximin - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 20 | 2020-09-18 | 2025-09-16 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer Alpha-tocopheryloxyacetic Acid, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 1 | Suspended | Veana Therapeutics | 24 | 2020-04-08 | 2024-07-10 |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Niraparib, Trastuzumab - Metastatic Breast Cancer, HER2 Positive Breast Carcinoma | Phase 1 / Phase 2 | Active not recruiting | University of Alabama at Birmingham | 46 | 2019-09-06 | 2026-01-23 |
| A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2 HER2 Positive Breast Carcinoma | Unknown | Anhui Provincial Hospital | 300 | 2019-04-10 | 2019-04-09 | |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 HER2 DC1 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 16 | 2019-01-10 | 2022-04-25 |
| T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer Palbociclib, T-DM1 - HER2-positive Breast Cancer, Breast Cancer | Phase 2 | Completed | University of Arizona | 55 | 2018-12-06 | 2024-08-13 |
| HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery - Breast Cancer, Breast Cancer Female | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 31 | 2018-06-06 | 2026-09-23 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases RC48-ADC, Lapatinib, Capecitabine - Breast Neoplasms, Breast Diseases | Phase 2 / Phase 3 | Unknown | RemeGen Co., Ltd. | 301 | 2018-04-24 | 2024-02-20 |
| Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer DC1 Vaccine, WOKVAC Vaccine - Breast Cancer Female, Breast Cancer, Male | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 119 | 2018-02-19 | 2026-03-06 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Estrogen Receptor Negative, HER2 Positive Breast Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 120 | 2017-01-20 | 2026-09-25 |
| Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer Comprehensive Geriatric Assessment, Laboratory Biomarker Analysis, Neratinib - HER2 Positive Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 | Phase 2 | Completed | City of Hope Medical Center | 25 | 2016-12-02 | 2023-06-18 |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab - HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | City of Hope Medical Center | 18 | 2016-07-15 | 2025-11-14 |
Showing 20 of 24. Sign in to see all of them.
Breast Neoplasms (16) · Breast Neoplasms, Male (3) · Triple Negative Breast Neoplasms (2) · Breast Diseases (1) · Insulin-Like Growth Factor I, Resistance To (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1)
Neoplasms (17) · Neoplasms by Site (17) · Skin Diseases (17) · Skin and Connective Tissue Diseases (17) · Breast Diseases (16) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Breast Neoplasms (1)
Trastuzumab (6) · PF-05280014 (5) · Ado-Trastuzumab Emtansine (4) · Lapatinib (3) · Ogivri (3) · Capecitabine (2) · Cyclophosphamide (2) · Immunotherapy (2) · Ontruzant (2) · Paclitaxel (2) · Taxes (2) · trastuzumab biosimilar HLX02 (2) · 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid (1) · 2C4 antibody (1) · 64Cu-DOTA-trastuzumab (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · Anhui Provincial Hospital (1) · Chongqing General Hospital (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · George W. Sledge Jr. (1) · Heinrich-Heine University, Duesseldorf (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · RemeGen Co., Ltd. (1)
United States (18) · Canada (2) · China (2) · Germany (1) · Italy (1) · Peru (1) · Puerto Rico (1) · South Africa (1) · Spain (1)
Amulya Yellala, MD (1) · Ciara C O'Sullivan (1) · Ciara C. O'Sullivan, MB, BCh, BAO (1) · Edith A Perez (1) · Erica Stringer-Reasor, M.D. (1) · George Sledge, MD (1) · Harold J Burstein (1) · Haten Soliman, M.D. (1) · Henry M Kuerer (1) · Hyo S. Han, M.D. (1) · Joanne Mortimer (1) · Mina Sedrak, MD (1) · Pavani Chalasani, MD (1) · Ricardo Costa, M.D. (1) · Saranya Chumsri, M.D. (1)
PMID 16236738, PMID 22042958, PMID 25332249, PMID 25348000, PMID 25605861, PMID 26101239, PMID 26429296, PMID 26469139, PMID 29898752, PMID 30808774, PMID 31622131, PMID 33663941, PMID 33796451, PMID 33852121, PMID 34636255, PMID 34980541, PMID 35610260, PMID 35617923, PMID 36306810, PMID 37707811, PMID 39191270, PMID 40073831, PMID 40097486, PMID 40152443, PMID 42802176
U10CA180821 (4), U10CA025224 (2), K12CA001727 (1), P30CA015083 (1), P30CA033572 (1), P30CA036727 (1), U10CA031946 (1)